State of New Jersey Common Pension Fund D Sells 29,363 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

State of New Jersey Common Pension Fund D reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 37.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,177 shares of the biopharmaceutical company’s stock after selling 29,363 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Halozyme Therapeutics were worth $2,575,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Halozyme Therapeutics by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 13,259,514 shares of the biopharmaceutical company’s stock worth $490,072,000 after buying an additional 152,870 shares during the last quarter. TD Asset Management Inc grew its position in shares of Halozyme Therapeutics by 28.1% in the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock worth $103,379,000 after buying an additional 557,350 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Halozyme Therapeutics by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock valued at $59,622,000 after purchasing an additional 145,879 shares during the period. Stephens Investment Management Group LLC lifted its stake in shares of Halozyme Therapeutics by 4.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,518,455 shares of the biopharmaceutical company’s stock valued at $56,122,000 after purchasing an additional 63,748 shares during the period. Finally, Epoch Investment Partners Inc. lifted its stake in shares of Halozyme Therapeutics by 23.3% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock valued at $58,319,000 after purchasing an additional 270,579 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at $834,836.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of the business’s stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at $834,836.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $55.12, for a total value of $551,200.00. Following the sale, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at approximately $9,269,861.12. The disclosure for this sale can be found here. Insiders sold 84,881 shares of company stock valued at $4,888,184 over the last 90 days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $62.31 on Thursday. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $65.53. The firm has a market capitalization of $7.93 billion, a P/E ratio of 25.75, a PEG ratio of 0.57 and a beta of 1.28. The business has a fifty day moving average of $58.14 and a 200 day moving average of $48.95.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The company had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. During the same quarter in the previous year, the company posted $0.68 earnings per share. Halozyme Therapeutics’s revenue was up 4.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 3.7 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on HALO. HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of Halozyme Therapeutics in a research note on Friday, September 13th. Piper Sandler cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $48.00 to $51.00 in a research note on Friday, June 7th. Benchmark reiterated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. The Goldman Sachs Group lifted their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Finally, TD Cowen lifted their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $59.44.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.